Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 1, 1997, Pages 73-82

  Perrault, Gh ^a   Depoortere, R ^a   Morel, E ^a   Sanger, D J ^a   Scatton, B ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; AMISULPRIDE; APOMORPHINE; BENZAMIDE DERIVATIVE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PRESYNAPTIC RECEPTOR; QUINPIROLE; REMOXIPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CLIMBING; CONTROLLED STUDY; DOSE RESPONSE; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC SYSTEM; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION; YAWNING;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BODY TEMPERATURE; DEXTROAMPHETAMINE; DOPAMINE ANTAGONISTS; GROOMING; LIMBIC SYSTEM; MALE; MICE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, PRESYNAPTIC; SULPIRIDE;

EID: 0030933627     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. 2 receptor mRNA. Brain Res. 564: 203-219, 1991.
2. BOYER, P., LECRUBIER, Y., PUECH, A., LAFERRIERE, N. AND FLEUROT, O.: Treatment of dysthymia with low-dose amisulpride versus amineptine. Clin. Neuropharmacol. 15: suppl. 1: 524B, 1992.
3. BOYER, P., LECRUBIER, Y., PUECH, A. J., DEWAILLY, J. AND AUBIN, F.: Treatment of negative symptoms in schizophrenia with amisulpride. Br. J. Psychiatry 166: 68-72, 1995.
4. CARLSSON, A.: Antipsychotic drugs, neurotransmitters and schizophrenia. Am. J. Psychiatry 135: 164-173, 1978.
5. CARNOY, P., RAVARD, S., WEMERMAN, B., SOUBRIE, PH. AND SIMON, P.: Behavioral deficits induced by low doses of apomorphine in rats: Evidence for a moti- vational and cognitive dysfunction which discriminates among neuroleptic drugs. Pharmacol. Biochem. Behav. 25: 503-509, 1986.
6. CHESHER, G. B. AND JACKSON, D. M.: Swim-induced grooming in mice is mediated by a dopaminergic substrate. J. Neural. Transm. 50: 47-55, 1981.
7. COLBOC, O. AND COSTENTIN, J.: Evidence for thermoregulatory dopaminergic receptors located in the preopticus medialis nucleus of the rat hypothalamus. J. Pharm. Pharmacol. 32: 624-629, 1980.
8. COSTALL, B. AND OLLEY, J. E.: Cholinergic- and neuroleptic-induced catalepsy: Modification by lesions in the caudate-putamen, Neuropharmaculogy 10: 297-306, 1971.
9. COSTALL, B. AND NAYLOR, R. J.: On the mode of action of apomorphine. Eur. J. Pharmacol. 21: 350-361, 1973.
10. COSTALL, B., NAYLOR, R. J., CANNON, J. G. AND LEE, T.: Differentiation of the dopamine mechanisms mediating stereotyped behaviour and hyperactivity in the nucleus accumbens and caudate-putamen. J. Pharm. Pharmacol. 29: 337-342, 1977.
11. COSTALL, B., NAYLOR, R. J. AND NOHRIA, V.: Climbing behaviour induced by apomorphine in mice: A potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 50: 39-50, 1978.
12. COSTENTIN, J., PROTAIS, P. AND SCHWARTZ, J. C.: Rapid and dissociated changes in sensitivities of different dopamine receptors in mouse brain. Nature (Lond.) 257: 405-407, 1975.
13. CSERNANSKY, J. G., WRONA, C. T., BARDGETT. M. E., EARLY, T. S. AND NEWCOMER, J. W.: Subcortical dopamine and aerotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. Psychopharmacology 110: 145-151, 1993.
14. 3 receptor ligand. Eur. J. Pharmacol. 249: R9-R10, 1993.
15. DELCKER, A., SCHOON, M. L., OCZKOWSKI, B. AND GAERTNER, H. J.: Amisulpride versus haloperidol in treatment of schizophrenic patients - Results of a double-blind study. Pharmacopaychiatry 23: 125-130, 1990.
16. 3 receptor agonist 7-OH-DPAT; Comparison with quinpirole and apomorphine. Psychopharmacology 124: 231-240, 1996.
17. DICHIARA, G., PORCEDDU, M. L., VARGIU, L., ARGIOLAS, A. AND GESSA, G. L.: Evidence for dopamine receptors mediating sedation in the mouse brain. Nature (Lond.) 264: 564-567, 1976.
18. DOURISH, C. T. AND HUTSON, P. H.: Bilateral lesions of the striatum induced with 6-hydroxydopamine abolish apomorphine-induced yawning in rats. Neuropharmacology 24: 1051-1055, 1985.
19. EILAM D. AND SZECHTMAN, H.: Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur. J. Pharmacol. 161: 151-157, 1989.
20. ERNST, A. M.: Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia 10: 316-323, 1967.
21. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch. Gen Psychiatry 49: 538-544, 1992.
22. FEENSTRA, M. G. P., SUMNERS, C., GOEDEMOED, J. H., DE VRIES, J. B., ROLLEMA, H. AND HORN, A. S.: A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity. Naunyn-Schmiedeberg's Arch. Pharmacol. 324: 108-115, 1983.
23. FUXE, K. AND SJÖQVIST, F.: Hypothermic effect of apomorphine in the mouse. J. Pharm. Pharmac. 24: 702-705, 1972.
24. GUYON, A., ASSOULY-BESSE, F., BIALA, G., PUECH, A. J. AND THIÉBOT, M. H.: Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rata. Psychopharmacology 110: 460-466, 1993.
25. KELLY, P. H., SEVIOUR, P. W. AND IVERSEN, S. D.: Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94: 507-522, 1975.
26. 3H-spiperone binding in vivo: Biochemical and behavioural evidence for a preferential action on limbic and nigral dopamine receptors. Neurosci. Lett. 13: 51-56, 1979.
27. 3 receptor agonists, 7-OH-DPAT, and quinpirole on yawning, stereotypy, and body temperature in rats. Pharmacol. Biochem. Behav. 52: 503-508, 1995.
28. 3 receptor mRNA and binding sites in human brain. Molecular Brain Res. 18: 187-192, 1993.
29. MELLER, E., HIZAMI, R. AND KREUTER, L.: Hypothermia in mice: D2 dopamine receptor mediation and absence of spare receptors. Pharmacol. Biochem. Behav. 32: 141-145, 1989.
30. MENON, M. K., CLARK, W. G. AND CANNON J. G.: Hypothermic effects of apomorphine homologues in mice. J. Pharm. Pharmacol. 31: 318-321, 1979.
31. 3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur. J. Pharmacol. 260: R3-R5, 1994.
32. 2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 275: 885-898, 1995.
33. MOGILNICKA, E. AND KLIMEK, V.: Drugs affecting dopamine neurons and yawning behaviour. Pharmac. Biochem. Behav. 7: 303-305, 1977.
34. MOGILNICKA, E., BOISSARD, C. G. AND DELINI-STULA, A.: Effects of apomorphine. TL-99 and 3-PPP on yawning in rats. Neuropharmacology 23: 19-22, 1984.
35. 1 antagonist SCH 23390. Psychopharmacology 82: 409-410, 1984.
36. MOORE, N. A. AND AXTON, M. S.: The role of multiple dopamine receptors in apomorphine and N-n-propylnorapomorphine-induced climbing and hypothermia. Eur. J. Pharmacol. 178: 195-201, 1990.
37. MUSCAT, R., TOWELL, A. AND WINNER, P.: Changes in dopamine autoreceptor sensitivity in animal model of depression. Psychopharmacology 94: 545-550, 1988.
38. 1 receptor antagonists. Eur. J. Pharmacol. 219: 35-44, 1992.
39. ÖRGEN, S. O., HALL, H., KÖHLER, C., MAGNUSSON, O., LINDBOM, L. O., ANGEBY, K. AND FLORVALL, L.: Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur. J. Pharmacol. 102: 459-474, 1984.
40. ÖGREN, S. O., FLORVALL, L., HALL, H., MAGNUSSON, O. AND ANGEBY-MÖLLER, K.: Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr. Scand. 82: suppl. 358, 21-26, 1990.
41. PHOTAIS, P., COSTENTIN, J. AND SCHWARTZ, J. C.: Climbing behaviour induced by apomorphine in mice: A simple test for the study of dopamine receptors in striatum. Psychopharmacology 50: 1-6, 1976.
42. PUECH, A. J., RIOUX, P., PONCELET, M., BROCHET, D., CHERMAT, R. AND SIMON, P.: Pharmacological properties of new antipsychotic agents: Use of animal models. Neuropharmacology 20: 1279-1284, 1981.
43. 2 receptor agonists with high and low efficacies. Eur. J. Pharmacol. 211: 9-14, 1992.
44. SANGER, D. J. AND PERRAULT, GH.: Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. J. Pharmacol. Exp. Ther. 272: 708-713, 1995.
45. 2 receptors. NeuroReport 6: 329-332, 1995.
46. SCATTON, B., BISCHOFF, S., DEDEK, J. AND KORF, J.: Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity. Eur. J. Pharmacol. 44: 287-292, 1977.
47. SCATTON, B.: Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: Evidence against dopamine receptor multiplicity. J. Pharmacol. Exp. Ther. 220: 197-202, 1982.
48. 3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther., 1997.
49. SCHOTTE, A., JANSSEN, P. F. M., MEGENS, A. A. H. P. AND LEYSEN, J. E.: Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Research 631: 191-202, 1993.
50. 4. Neuropsychopharmacology 7: 261-284, 1992.
51. SERRA, G., ARGIOLAS, A., KLIMEK, V., FADDA, F. AND GESSA, G. L.: Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci. 25: 415-424, 1979.
52. SIBLEY, D. R. AND MONSMA, F. J., JR.: Molecular biology of dopamine receptors. Trends Pharmacol Sci. 13: 61-69, 1992.
53. 3) as a target for neuroleptics. Nature (Lond.) 347: 146-151, 1990.
54. 2 receptor. Eur. J. Pharmacol. Molecular. Pharmacol. Section 225: 331-337, 1992a.
55. 3 dopamine receptor. Arzneim. Forsch./Drug Res. 42: 224-230, 1992b.
56. STÄHLE, L.: Do autoreceptors mediate dopamine agonist induced yawning and suppression of exploration? A critical review. Psychopharmacology 106: 1-13, 1992.
57. STÄHLE, L. AND UNGERSTEDT, U.: Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by a low dose of apomorphine: Implications for the identity of dopamine receptors. Pharmacol. Biochem. Behav. 25: 473-480, 1986.
58. STÄHLE, L., LJUNGBERG, T., RODEBJER, A., OGREN S. O. AND UNGERSTEDT, U.: Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat. Pharmacol. Toxicol. 60: 227-232, 1987.
59. 4 receptor with high affinity for the antipsychotic clozapine. Nature (Lond.) 350: 610-614, 1991.
60. VAN WIMERSMA GREIDANUS, T. B., MAIGRET, C., TORN, M., RONNER, E., VAN DER KRACHT, S., VAN DER WEE, N. J. A. AND VERSTEEG, D. H. G.: Dopamine D-1 and D-2 receptor agonists and antagonists and neuropeptide-induced excessive grooming. Eur. J. Pharmacol. 173: 227-231, 1989.
61. VASSE, M., CHAGRAOUI, A. AND PROTAIS, P.: Climbing and stereotyped behaviours in mice require the stimulation of D-1 dopamine receptors. Eur. J. Pharmacol. 148: 221-229, 1988.
62. VASSE, M., PROTAIS, P., COSTENTIN, J. AND SCHWARTZ, J. C.: Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunyn-Schmied. Arch. Pharmacol. 329: 108-116, 1985.
63. WORMS, P. AND LLOYD, K. G.: Predictability and specificity of behavioral screening tests for neuroleptics. Pharmacol. Ther. 5: 445-450, 1979.
64. YAMADA, K. AND FUKUKAWA, T.: Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology 67: 39-43, 1980.
65. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 271: 1462-1470, 1994.
66. ZIVKOVIC, B., GUIDOTTI, A., REVUELTA, A. AND COSTA, E.: Effects of thioridazine. clozapine and other antipsychotics on the kinetic state of tyrosine hydroxylase and on the turnover rate of dopamine in striatum and nucleus accumbens. J. Pharmacol. Exp. Ther. 194: 37-46, 1975.